Medicare beneficiaries have already seen the first results of federal drug price negotiation: lower prices on 10 high-cost medications took effect January 1, 2026. Now, the Centers for Medicare and Medicaid Services is proposing to make the program that achieved those reductions permanent.
CMS issued Proposed Rule CMS-4215-P on June 12, 2026, which would transform the Medicare Drug Price Negotiation Program from a guidance-based pilot into a formal, durable regulatory framework. The rule would codify the program for all future negotiation cycles beginning with the initial price applicability year 2029, establishing clear and predictable procedures for how drugs are selected, how negotiations proceed, and how maximum fair prices are implemented.
Why This Matters
For millions of Medicare beneficiaries who take expensive brand-name medications, the drug price negotiation program represents the most significant structural change to prescription drug affordability in Medicare’s history. The Inflation Reduction Act of 2022 authorized the program, and the first negotiated prices took effect this year.
CMS Administrator Mehmet Oz framed the rule as a transition to stability: «We are moving from annual updates to a permanent, predictable framework. This approach puts patients first, strengthens Medicare, and protects the innovation pipeline that delivers future cures.»
Whether the program delivers meaningful savings for individual patients will depend on which drugs are selected in future cycles and how health plan formularies incorporate the negotiated prices.
What We Know So Far
The Medicare Drug Price Negotiation Program has now completed two negotiation cycles, producing negotiated prices for 25 high-expenditure drugs. According to AJMC, the second cycle produced a 44 percent average net savings — $12 billion against 2024 Medicare spending — on 15 drugs, including Ozempic and Wegovy, which received a 71 percent reduction off list price, effective January 1, 2027.
The 10 drugs with negotiated prices already in effect in 2026 span diabetes, heart failure, and blood clot prevention — conditions that affect tens of millions of Medicare beneficiaries. CMS reports those 10 drugs cost Medicare enrollees a combined $3.4 billion in out-of-pocket costs in 2022, and the negotiated prices are expected to generate roughly $1.5 billion in savings.
What the Proposed Rule Would Do
According to Duane Morris and the Federal Register, the rule would:
- Codify the drug selection process, negotiation procedures, manufacturer agreement requirements, and renegotiation criteria into permanent regulation — replacing the guidance documents that have governed each year
- Establish that Part D plans must include any selected drug with a maximum fair price in effect on their formularies, improving beneficiary access
- Cap what plans pay dispensing pharmacies at the maximum fair price, plus applicable fees
- Select up to 20 drugs per year for negotiation in each future cycle
- Create a temporary floor for small biotech products in negotiation cycles 2029–2030 to address concerns about disincentives to innovation
The comment period is open until August 17, 2026. The final rule is expected in fall 2026, with implementation beginning for the 2029 drug selection cycle.
Where the Impact Would Be Greatest
The negotiated prices matter most for Medicare beneficiaries who take high-cost, brand-name drugs with no generic alternatives — the exact category the Inflation Reduction Act targeted.
People with diabetes who use injectable medications like Ozempic or Victoza, people with heart conditions who rely on high-cost single-source drugs, and people with rheumatoid arthritis treated by biologic medications are among the groups most likely to see real out-of-pocket reductions.
Importantly, as Holland & Knight notes, the 2026 cycle’s negotiated prices only benefit patients who are enrolled in Part D plans. People in Medicare Advantage plans with drug coverage are included, but access may vary depending on how plans design their formularies.
What the Evidence Shows — and What It Does Not
The negotiated prices are real and verifiable — the maximum fair prices are publicly listed, and CMS has confirmed that prices for the first 10 drugs took effect on schedule. The question of how much individual beneficiaries save depends heavily on what their specific drug plan covers and how their cost-sharing is structured.
Some stakeholders have raised concerns that negotiated prices do not automatically translate to lower out-of-pocket costs for all patients. John Stanford of Incubate noted that «even with price controls in place, patients still can’t necessarily access those specific medicines» because insurance design, not list price, remains the operative barrier for many people.
Who Benefits Most?
Medicare beneficiaries most likely to see meaningful savings include:
- Part D enrollees who take one or more of the negotiated drugs and currently face high out-of-pocket costs
- People in the catastrophic coverage phase of Part D, where cost sharing was previously high for expensive drugs
- Beneficiaries with diabetes, heart conditions, blood clotting disorders, or rheumatoid arthritis — the conditions covered by first-cycle negotiated drugs
What You Can Do Now
- If you take a Medicare Part D drug that may be subject to negotiated pricing, ask your pharmacist or health plan whether the drug’s price has been negotiated and whether your cost-sharing reflects the lower price.
- During the next Open Enrollment period (October 15 to December 7, 2026), check whether your Part D plan includes any drugs with negotiated maximum fair prices on its formulary.
- If you want to comment on the proposed rule, public comments are due by August 17, 2026, and can be submitted through the Federal Register’s comment portal.
- Check Medicare.gov for updates on which drugs have been selected for negotiation and what their maximum fair prices are.
Cost and Access: What Patients Should Know
The negotiated prices represent a ceiling, not a guarantee, for individual cost-sharing. Patients should compare plan options during Open Enrollment to find the plan that best covers the drugs they take. Medicare’s Plan Finder tool at Medicare.gov allows beneficiaries to compare plans based on their specific prescription list.
For people with limited income, the Medicare Extra Help (Low-Income Subsidy) program can further reduce drug costs beyond the negotiated prices.
What Happens Next
The public comment period closes August 17, 2026. CMS expects to finalize the rule in fall 2026. The list of drugs selected for the 2029 negotiation cycle is expected to be released by February 1, 2027. Negotiated prices for 2028 will be released before November 30, 2026. MedicalDaily will report on both the final rule and the 2028 drug price announcements.
The Bottom Line
Medicare drug price negotiation is moving from a temporary pilot to a permanent federal program — and the first negotiated prices are already saving Medicare beneficiaries money on diabetes, heart failure, and rheumatoid arthritis medications. The proposed rule, released June 12, would formalize the process for years to come, providing predictability for both patients and drug manufacturers. Whether individual beneficiaries see meaningful savings will depend on which drugs enter the program and how their specific plans incorporate the negotiated prices.
